A Pilot Study of Active Immunotherapy With Carcinoembryonic Antigen Peptide-Pulsed, Autologous Human Cultured Dendritic Cells in Patients With Resected, Stage I, II and III Pancreatic Adenocarcinoma Expressing Carcinoembryonic Antigen

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed stage I, II, or III adenocarcinoma of
the pancreas Resected with no gross residual disease At least 50% of tumor cells must be
CEA positive and stain with at least moderate intensity HLA-A2 positive

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life
expectancy: Greater than 6 months Hematopoietic: Absolute neutrophil count at least
1000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL SGOT and alkaline phosphatase less than 4
times the upper limit of normal No hepatic failure Renal: Creatinine less than 2.0 mg/dL
OR Creatinine clearance greater than 50 mL/min Cardiovascular: No New York Heart
Association class III or IV heart disease Pulmonary: No concurrent asthma or chronic
obstructive pulmonary disease Other: No other malignancy except nonmelanoma skin cancer or
controlled superficial bladder cancer within the past 5 years No history of autoimmune
diseases such as inflammatory bowel disease, systemic lupus erythematosus, ankylosing
spondylitis, scleroderma, rheumatoid arthritis, or multiple sclerosis No active acute or
chronic infection such as urinary tract infection, HIV, or viral hepatitis No active
infectious enteritis or eosinophilic enteritis Not pregnant or nursing Fertile patients
must use effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since immunotherapy No other
concurrent immunotherapy Chemotherapy: At least 4 weeks since chemotherapy and recovered
No concurrent chemotherapy Endocrine therapy: No concurrent corticosteroid or
immunosuppressive therapy At least 6 weeks since steroid therapy Radiotherapy: At least 4
weeks since radiotherapy and recovered Surgery: Recovered from prior surgery